Inflammatory responses to checkpoint inhibitors, particularly when used in combination, are due to cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) regulating immune responses in both cancer and healthy cells. Here, PDCD1 is linked to cancer.